Alvarez & Marsal Managing Director Mark Freitas was featured among Top 25 Life Sciences Consultants and Leaders of 2024
The Consulting Report is pleased to announce The Top 25 Life Sciences Consultants and Leaders of 2024. The life sciences industry has undergone significant transformation in recent years, fueled by scientific breakthroughs, technological innovation, and the global impact of the COVID-19 pandemic. While these shifts have ushered in new opportunities for patient care, drug development, and medical innovation, they have also presented complex challenges. Life sciences organizations now face increased pressure to optimize pricing, navigate unpredictable market access, adapt to changing consumer behavior, and enhance operational efficiency.
Mark Freitas specializes in helping businesses reach their full potential by developing successful strategies that maximize growth while avoiding operational challenges. His expertise spans corporate finance and operations, strategic planning, board governance, mergers and acquisitions activity, risk management, and compliance.
Read the Full Article Here
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
Strategic Patience in GenAI - A smarter path to AI leadership
August 11, 2025
As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.
The U.S. Pharma Premium: Who’s Really Paying the Price?
June 30, 2025
For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.
When Security Creates Scarcity: DSCSA’s Unintended Consequence
June 2, 2025
In a recent article, A&M Life Sciences experts discuss The Drug Supply Chain Security Act and how well-intentioned regulations may be straining the very system they’re meant to safeguard.
